BioSpace News Archive

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™ , an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000

Flagship Biosciences, providers of expert tissue data insights, today announced that Aymii Couzelis has been named to its executive team as Chief Information Officer.

Central Admixture Pharmacy Services, Inc., the nation’s largest network of outsourcing admixture pharmacies, announced the expansion of its product portfolio.

Funding Will Support Delivery of Medically Tailored Meals to People Living with Kidney Failure and Those Struggling During COVID-19 Pandemic

Orphan drug designation granted for treatment (management) of pulmonary infections in patients with cystic fibrosis

HIV remodels its target cells, facilitating spread from the female reproductive tract to the rest of the body, shows a new study at Gladstone Institutes

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET. A

James Hindman, a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 2:30 p.m. EDT / 11:3

Cardiff Oncology, Inc. announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.